SOLANA BEACH, Calif. and REDWOOD CITY, Calif., June 24, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) today announced that the Company has terminated its employees and will wind down it operations, including seeking potential strategic alternatives for the Company's development programs. This decision was made at a special meeting of the board of directors. Further, as previously disclosed, the Company's securities do not presently meet the continued listing requirements of the Nasdaq ...

eFFECTOR Therapeutics (NASDAQ:EFTR) just reported results for the first quarter of 2024.eFFECTOR Therapeutics reported earnings per share of -$2.16. This met the analyst estimate for EPS of -$2.16.The company did not report any revenue for the quarter.InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst es ...

eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update Dose escalation of zotatifin in the ZFA triplet ongoing at 0.14 mg/kg, with RP2D expected in H2 2024 Raised $15.0 million in gross proceeds from registered direct financing, extending cash runway into first quarter of 2025 SOLANA BEACH and REDWOOD CITY, Calif., May 9, 2024 – eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treat ...

WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR UNITED STATES SECURITIES AND EXCHANGE COMMISSION ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39866 eFFECTOR Therapeutics, Inc. (Exact name of Registrant as specified in its Charter) Delaware 85-3306396 (State or other juri ...

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR), a leader in the development of selective translation regulator inhibitors ("STRIs") for the treatment of cancer, today announced that the Company will present at the Stifel Virtual Oncology Forum on Tuesday, April 16th at 11:30 am ET. A live webcast of the virtual presentation will be available on the "Events and Presentations" page of the Investors section of the Company's website wi ...

eFFECTOR Therapeutics, Inc. (EFTR) plunged 82% in the last trading session on Apr 4, after the company announced disappointing top-line results from the primary analysis of its mid-stage non-small cell lung cancer (NSCLC) study. Consequently, the company has abandoned the tomivosertib development program in frontline NSCLC.The randomized phase II KICKSTART study is evaluating the safety and efficacy of its investigational candidate, tomivosertib, in comparison with placebo, each administered in combination ...

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced topline results from the primary analysis of the randomized Phase 2 KICKSTART trial which tested tomivosertib or placebo, each combined with pembrolizumab, as frontline treatment for patients with non-small cell lung cancer (NSCLC) with PD-L1 ≥50%. Based on 36 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39866 eFFECTOR Therapeutics, Inc. (Exact name of Registrant as specified in its Charter) Delaware 85-3306396 (State or other jurisdiction of incorporation or organization) 142 North Cedros Avenue, Suite B Solana Beach, CA 92075 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION ...

Exhibit 99.1 eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update Topline data from the randomized Phase 2b KICKSTART trial of tomivosertib combined with pembrolizumab in non-small cell lung cancer (NSCLC) expected in early April 2024 Median progression free survival (mPFS) of 7.4 months in the ZFA expansion cohort evaluating zotatifin in combination with fulvestrant and abemaciclib in heavily pretreated patients Received U.S. FDA Fast Track designa ...

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR), a leader in the development of selective translation regulator inhibitors ("STRIs") for the treatment of cancer, today announced that Steve Worland, Ph.D., president, and chief executive officer of eFFECTOR, will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Wednesday, February 14th at 10:40 am ET. A live webcast of the virtual presentations will be avai ...